Gaithersburg, MD, May 4, 2017 – Altimmune, Inc. (Nasdaq: ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed Altimmune, Inc., and will commence trading on The NASDAQ Capital Market under the ticker symbol “ALT” on May 5, 2017. The combined company is a fully integrated and diversified immunotherapeutics company with one preclinicalstage and four clinical-stage drug-development programs. Bill Enright, President and Chief Executive Officer of Altimmune, and Elizabeth Czerepak, Chief Financial Officer and Executive Vice President of Corporate Development of Altimmune, will serve in their respective positions in the combined company. The new board of directors will be initially comprised of three PharmAthene directors and four Altimmune directors. The combined company’s headquarters is located in Gaithersburg, MD. Additionally, the company announced that immediately prior to the merger, it effectuated a 1-for- 10 reverse stock split of outstanding shares of its common stock. As a result of the reverse stock split, each 10 shares of common stock outstanding immediately prior to the merger were converted into one share of common stock. Mr. Enright stated: “We congratulate and thank the employees and shareholders of both companies for their approval of this merger, which will bring together complementary vaccine development programs and allow us to leverage our substantial financial and human resources effectively in support of these programs.” Contact: Matthew Duffy Investor Relations 212-915-0685 matthew@lifesciadvisors.com Altimmune will focus its drug-development activities on the following proprietary vaccine candidates: • NasoVAX: an intranasal, single dose, state-of-the-art recombinant influenza vaccine that in preclinical studies demonstrated early and universal activity. Phase 2 is expected to commence during 3Q2017 with initial data expected in 1Q18. • HepTcell: a first-in-class immunotherapeutic for chronic hepatitis B with the potential to offer a functional cure. Phase 1 is ongoing with initial data expected 4Q17. • SparVax-L: a next generation lyophilized anthrax vaccine (NIAID funded) that may be stored at room temperature and provides extended shelf life. A non-human primate bridging study is anticipated to begin during the second half of 2017 with data anticipated during the first half of 2018. • NasoShield: an intranasal, single-dose, first-in-class anthrax vaccine (BARDA funded) that based on preclinical studies may offer protection within a few weeks of administration. A Phase 1 trial is expected to begin during 1Q18 with data anticipated 2Q18. • In addition to the clinical-stage product candidates, Altimmune has one preclinical program, Oncosyn, driven by its proprietary Densigen synthetic peptide technology that is being evaluated in immuno-oncology indications. About Altimmune, Inc. Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Forward-Looking Statement Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the amount of Altimmune’s net cash, the prospects for commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PharmAthene, Altimmune or the management of either company, before or after the aforementioned merger, may identify forward-looking statements. The company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Altimmune to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of Altimmune’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that Altimmune may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect Altimmune’s business, financial conditions and results of operations are contained in the company’s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

Contact: Matthew Duffy Investor Relations 212-915-0685 matthew@lifesciadvisors.com

Swedish HealthCap V portfolio company MIPS AB has successfully completed its oversubscribed Initial Public Offering on Nasdaq OMX Stockholm’s main market. The total deal size is EUR 59 million (SEK 570 million) of which the company is raising EUR 15 million (SEK 150 million) in gross proceeds. HealthCap and other major investors committed to sell in the IPO shares corresponding to the remaining EUR 44 million (SEK 420 million) of deal size.  In addition, existing major investors have also committed to sell in the potential utilization of the over-allotment option that corresponds to 15% of the offer size.

MIPS AB is a spin-off from the Division of Neuronic Engineering at the Royal Institute of Technology in Stockholm developing a solution applied in safety helmets to prevent or reduce skull and brain injuries by from oblique impacts. HealthCap V made its initial investment in MIPS in March, 2008 and has to date invested EUR 3.4 million for a post-IPO ownership of approximately 9.8%, excluding any sales of shares in the overallotment option. At the IPO price of SEK 46 per share, the market capitalization of the company reaches approximately EUR 120 million (SEK 1,164 million) and the gross multiple on HealthCap’s investment in MIPS is 6.2x.

The shares will commence trading today under the ticker “MIPS”.

January 19, 2017 6:30 AM ET

ANNAPOLIS, Md. and GAITHERSBURG, Md., Jan. 19, 2017 /PRNewswire/ — PharmAthene, Inc. (NYSE MKT: PIP)
and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced today the
signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune’s
current investors include Novartis Venture Fund, HealthCap, Truffle Capital and Redmont Capital. The combined
company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one
preclinical stage programs. The proposed transaction does not affect PharmAthene’s previously announced special
one-time cash dividend of $2.91 per share of common stock.

“A merger with Altimmune is an ideal strategic match. It fulfills our stated goal of continuing to build value for
PharmAthene shareholders after we distribute the SIGA litigation proceeds on February 3,” commented John M. Gill,
President and Chief Executive Officer of PharmAthene. “By combining forces, we will diversify our portfolio into
attractive commercial product opportunities and leverage our capabilities for developing next generation anthrax vaccines.”
Bill Enright, President and Chief Executive Officer of Altimmune, added, “The merger allows Altimmune to leverage
PharmAthene’s existing U.S. public company infrastructure, providing access to the capital markets, which is essential to
the continued development of immunotherapeutics clinical programs including NasoVAX, NasoShield and HepTCell that
leverage Altimmune’s proprietary platform technologies.”

Details of Proposed Merger
The merger has been unanimously approved by both Boards of Directors and is subject to the approval of PharmAthene
and Altimmune shareholders, and other customary closing conditions. Under the terms of the merger, Altimmune will
become a wholly-owned subsidiary of PharmAthene in an all-stock transaction. PharmAthene will issue shares of common
stock to Altimmune shareholders such that Altimmune equity holders will own 58.2% of the fully-diluted equity of the
combined company. The combined company, which will operate as a public company under the name Altimmune, is
expected to trade on the NYSE MKT under the ticker symbol ALT.

Bill Enright, Chief Executive Officer of Altimmune, and Elizabeth Czerepak, Chief Financial Officer and Executive Vice
President of Corporate Development of Altimmune, will serve in their respective positions for the combined company.
The new Board of Directors will be initially comprised of three PharmAthene directors and four Altimmune directors. The
combined company’s headquarters will be located in Gaithersburg, MD. At closing the combined company is expected to
have approximately $20 million in cash and cash commitments.

Clinical Stage Product Pipeline
The combined company’s clinical stage product candidates following the merger will include:

• NasoVAX: an intranasal, single dose, state-of-the-art recombinant influenza vaccine that in preclinical studies
  demonstrated early universal activity. Phase 2 is expected to commence during mid-2017 with initial data expected
  in 4Q17.
• HepTcell: a first-in-class immunotherapeutics for chronic hepatitis B with the potential to offer a functional cure.
  Phase 1 is ongoing with data expected 4Q17.
• SparVax-L: a next generation lyophilized anthrax vaccine (NIAID funded) that may be stored at room temperature
  and provides extended shelf life. A Phase 2 bridging study is anticipated to begin during the second half of 2017
  with data anticipated during 2018.
• NasoShield: an intranasal, single dose, first-in-class anthrax vaccine (BARDA funded) that based on preclinical
  studies may offer protection within a few weeks of administration. A Phase 1 trial is expected to begin during the
  second half of 2017 with data anticipated during the first half of 2018.

Preclinical Product Pipeline

• In addition to the clinical stage product candidates, the combined company has one preclinical program, Oncosyn,
  driven by Altimmune’s proprietary Densigen synthetic peptide technology investigating the utility of this platform
  in immuno-oncology indications.

Piper Jaffray & Co. has acted as an advisoron the transaction to Altimmune.

Important Additional Information about Proposed Merger
This communication is being made in respect of the proposed merger involving PharmAthene, Inc. and Altimmune, Inc.
PharmAthene will file with the Securities and Exchange Commission, or SEC, a current report on Form 8-K, which will
include the merger agreement and related documents. In addition, PharmAthene intends to file a registration statement on
Form S-4 with the SEC, which will contain a joint proxy statement/prospectus and other relevant materials, and plans to
file with the SEC other documents regarding the proposed transaction. The final joint proxy statement/prospectus will be
sent to the stockholders of PharmAthene and Altimmune. The joint proxy statement/prospectus will contain information
about PharmAthene, Altimmune, the proposed merger and related matters. STOCKHOLDERS ARE URGED TO READ
THE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS)
AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY
BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS
SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT THE MERGER AND RELATED MATTERS. In
addition to receiving the joint proxy statement/prospectus and proxy card by mail, stockholders will also be able to obtain
the joint proxy statement/prospectus, as well as other filings containing information about PharmAthene, without charge,
from the SEC’s website (http://www.sec.gov) or, without charge, by directing a written request to: PharmAthene, Inc.,
One Park Place, Suite 450, Annapolis, Maryland 21401, Attention: Investor Relations.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer
to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of
securities in connection with the proposed merger shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in Solicitation

PharmAthene and its executive officers and directors may be deemed to be participants in the solicitation of proxies from
PharmAthene’s stockholders with respect to the matters relating to the proposed merger. Altimmune and its officers and
directors may also be deemed a participant in such solicitation. Information regarding PharmAthene’s executive officers
and directors is available in PharmAthene’s proxy statement on Schedule 14A, filed with the SEC on April 29, 2016.
Information regarding any interest that PharmAthene, Altimmune or any of the executive officers or directors of
PharmAthene or Altimmune may have in the transaction with Altimmune will be set forth in the joint proxy
statement/prospectus that PharmAthene intends to file with the SEC in connection with its stockholder vote on matters
relating to the proposed merger. Stockholders will be able to obtain this information by reading the joint proxy
statement/prospectus when it becomes available.

About PharmAthene, Inc.
PharmAthene is engaged in the development of a next generation anthrax vaccine that is intended to improve protection
and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

About Altimmune, Inc.
Altimmune is a clinical stage immunotherapeutics company focused on the development of products to stimulate robust
and durable immune responses for the prevention and treatment of disease. The company has two proprietary platform
technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different
ways than traditional vaccines.

PharmAthene Forward-Looking Statement Disclosure
Any statements made in this press release relating to future financial or business performance, conditions, plans,
prospects, trends, or strategies and other financial and business matters, including without limitation, the potential closing
date of the transaction, the amount of PharmAthene’s net cash at closing, the prospects for commercializing or selling any
products or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PharmAthene,
Altimmune or the management of either company, before or after the aforementioned merger, may identify forwardlooking
statements. PharmAthene and Altimmune caution that these forward-looking statements are subject to numerous
assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ
materially from the results discussed in the forward-looking statements or historical experience include risks and
uncertainties, including the failure by PharmAthene or Altimmune to secure and maintain relationships with collaborators;
risks relating to clinical trials; risks relating to the commercialization, if any, of PharmAthene’s or Altimmune’s proposed
product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on
the efforts of third parties; dependence on intellectual property; and risks that PharmAthene or Altimmune may lack the
financial resources and access to capital to fund proposed operations. Further information on the factors and risks that
could affect PharmAthene’s business, financial conditions and results of operations are contained in PharmAthene’s filings
with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

Other risks and uncertainties are more fully described in PharmAthene’s Annual Report on Form 10-K for the year ended
December 31, 2015 filed with the SEC, and in other filings that PharmAthene makes and will make with the SEC in
connection with the proposed transactions, including the Joint Proxy Statement/Prospectus described above under
“Important Additional Information about Proposed Merger.” Existing and prospective investors are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the date hereof. The statements made herein
speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs
to change. While we may elect to update these forward-looking statements publicly at some point in the future, we
specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as
required by law. These forward-looking statements should not be relied upon as representing our views as of any date
after the date stated herein.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmatheneand-
altimmune-announce-merger-to-create-immunotherapeutics-company-targeting-infectious-diseases-300393398.html

SOURCE PharmAthene, Inc.

PharmAthene, Inc.: Melody A. Carey, Investor Relations, 917-322-2571, mcarey@rxir.com; Altimmune, Inc.: Bill Enright,
President and Chief Executive Officer, 240-654-1450, enright@altimmune.com

Tieto strengthens its position as a business renewal partner for financial services customers – acquires Emric

Tieto has signed an agreement to acquire Emric, the Nordic market leader in software and services for credit processing. The acquisition will strengthen Tieto’s position as a business renewal partner for Nordic financial services customers. It is expected to contribute to both the company’s ambition to accelerate its scalable software business and progress towards its profitability targets.

The transaction supports the company’s financial services business expansion in the Nordic countries and internationally. Furthermore, it accelerates Tieto’s Banking as a Service offering through new competencies and software products within loan origination, lending and leasing.

“The acquisition will further strengthen our software-based business in the attractive modernization market in the Nordic countries and Europe. With our combined offerings we can provide the full value chain to our Nordic banking and finance customers within retail banking and consumer finance markets. We warmly welcome our new colleagues from Emric to Tieto in our common mission to accelerate innovation and value for customers”, says Per Johanson, Executive Vice President, Financial Services, Tieto.

“We are very excited to join forces with Tieto. By combining Tieto’s capabilities and strong presence with Emric’s market leading lending and leasing products and services, we will further strengthen our joint customer value proposition”, says Pedram Tadayon, CEO of Emric.

In 2015, Emric’s net sales amounted to SEK 185 million (EUR 19.5 million). In 2015, approximately 65% of its net sales came from Sweden and the rest from Finland, Norway, Denmark, Iceland and other European countries. Tieto expects the Emric acquisition to be accretive to Tieto’s growth and profit targets as from 2017. Emric has offices in Stockholm, Kalix and Belgrade, with around 200 employees.
The acquisition has been completed. The up-front acquisition price, paid in cash at the closing, is based on Enterprise Value (EV) of SEK 300 million. Additionally, the parties have agreed on an earn-out model based on Emric’s performance during 2017 and 2018.
For further information, please contact:

Per Johanson, Executive Vice President, Tieto Financial Services and Country Manager, Tieto Sweden, mobile: +46 768 21 2029, per.johanson(at)tieto.com
Investors: Lasse Heinonen, CFO, tel. +358 2072 66329, +358 50 393 4950, lasse.heinonen(at)tieto.com

Media: Kia Haring, Head of Global Communications, tel. +358 40 765 3700, kia.haring(at)tieto.com

Pedram Tadayon, CEO, Emric, tel. +46 70 685 55 88, pedram.tadayon(at)emric.com

Tieto aims to capture the significant opportunities of the data-driven world and turn them into lifelong value for people, business and society. We aim to be customers’ first choice for business renewal by combining our software and services capabilities with a strong drive for co-innovation and ecosystems.

Headquartered in Finland, Tieto has over 13 000 experts in close to 20 countries. Tieto’s turnover is approximately EUR 1.5 billion and shares listed on NASDAQ in Helsinki and Stockholm. www.tieto.com

About Emric

Emric supports a global network of banks, credit companies and system partners to incorporate a superior value chain for lending and leasing into their business. Headquartered in Stockholm, the company has additional business operations in Kalix and Belgrade.
With approximately EUR 20 million in revenue, installations in 24 different countries and 60 individual banks and credit companies as clients, Emric is the largest vendor in Scandinavia in its segment. Main owners were InnovationsKapital, Fredrik Månson and Öhman. www.emric.com

A research Institute in China in the name of our Senior Advisor Bengt Samuelsson, Professor of Physiological Chemistry and former President of the Karolinska Institute. . Professor Samuelsson was awarded the Nobel Prize in 1982 for his research.

Significant funding has been made available to the research institute which will focus on the incubation and industrialization of biomedical and pharmaceutical projects with initial focus on anti-inflammatory proteins

Peter Gajdos Tapped as Managing Director, Lee Pantuso as CFO, Firm Announces Presidio Partners 2014 Fund

SAN FRANCISCO, April 21, 2015 – Presidio Partners, formerly CMEA Capital, today unveiled a new corporate identity, announced the promotion of Peter Gajdos to the role of Managing Director and the appointment of Lee Pantuso as Chief Financial Officer, and announced the closing of Presidio Partners 2014. This new fund — which is focused on information technology, life sciences and energy technology investments — resulted from a restructuring of CMEA legacy funds IV, V and VI, with additional follow-on capital. In addition, the CMEA VII fund has been renamed Presidio Partners 2007.
In Presidio Partners 2007, a $400 million fund, the team currently manages 19 companies, two public and 17 private. In Presidio Partners 2014, a $142 million fund, there are currently 17 companies, three public and 14 private.

Concurrent with the Presidio Partners 2014 fund announcement, the firm unveiled a new corporate identity. For more information, please visit Presidio Partners’ new website, which can be found at www.presidiopartners.com.

“We’ve made some important additions to our team and changes to our business approach,” said Jim Watson, Presidio Partners’ CEO and Managing Director. “Our
Presidio Partners team takes the deep sector expertise and learnings of 25 years of venture capital and blends them with operational experience in both startups and large companies, as well as with best practices in building and monetizing great companies. We took what we believed worked, left behind what we believed didn’t, and added some differentiated new capabilities — in particular around portfolio management — that we believe will better enable us to help portfolio companies successfully tackle the business challenges of the coming decade.”

Newly promoted Managing Director Peter Gajdos actively manages Presidio Partners’ public company portfolio. He serves as a knowledge resource in agriculture, solar, water, 3D printing, material technologies and energy storage, supporting entrepreneurs at every stage of the corporate life cycle. Gajdos was involved in Presidio Partners’ efforts backing Auspex (NASDAQ: ASPX) and Ardelyx (NASDAQ: ARDX), and has served as a board member at Arcadia Biosciences, Cnano Technology, Reel Solar (acquired by a Chinese strategic investor), Neos Therapeutics (observer), Exela Pharma Sciences (observer), and Wildcat Discovery Technologies (observer). Gajdos began his career at JP Morgan in New York, where he advised on M&A and IPO transactions in North and Latin America. He then joined Virgin Green Fund in London, a fund backed by Sir Richard Branson’s Virgin Group.

Another key member of the expanded Presidio Partners team is Chief Financial Officer Lee Pantuso. She is responsible for the accounting, financial reporting, tax preparation, and internal and external compliance issues for all Presidio Partners-related entities. Pantuso began her career in public accounting with Arthur Andersen and has held a number of corporate domestic and international accounting and finance positions, including CFO of NeoCarta Ventures, CFO of Big Data analysis start-up Cataphora, and CFO of online sports pick platform company PicksPal.

About Presidio Partners
Presidio Partners is a San Francisco-based venture capital firm with a diversified investment strategy focused on information technology, life sciences and energy
technology that allows for consistency in returns and the ability to capitalize on trends in various sectors as they play out over a fund’s life. The firm strives to introduce innovative portfolio management practices to venture investing. Learn more by visiting www.presidiopartners.com.

Media Contact:
Lisa Hawes, Sterling Communications
lhawes@sterlingpr.com
408-395-5500
Other Inquiries:
Victoria Jenks, Presidio Partners
rory@presidiopartners.com
415-963-3325

Former head of Google China, Kai-fu Lee, insists—insists—that he is not happy that Google imploded its business in China.

Psilos Group announced that Ingenix, a leading health information, technology, consulting and services company

It is time to develop a realistic plan for positive and durable healthcare reform